Five doses of inactivated
Infection due to Mycobacterium tuberculosis is a major cause of morbidity and mortality among HIV-infected persons in many areas of the world and is an especially significant problem in developing countries. Chemoprophylaxis for 6-12 months is effective in reducing short-term rates of active tuberculosis in HIV-infected adults [1] [2] [3] but is not universally available and will not reduce rates of new infection with M. tuberculosis after cessation of prophylaxis. Immunization with live Mycobacterium bovis BCG reduces the risk of disease due to M. tuberculosis in healthy subjects [4] and may reduce the risk of bacteremic tuberculosis in some HIV-infected adults [5] . However, BCG cannot be administered to adults with known HIV infection or children with symptomatic AIDS because of the risk of disseminated BCG disease [6, 7] . An improved vaccine for prevention of tuberculosis in HIV-infected persons is needed.
Heat-inactivated M. vaccae is an investigational vaccine prepared from an environmental mycobacterium that shares numerous antigens with other nontuberculous mycobacteria and with M. tuberculosis [8] . In animal studies, M. vaccae has been shown to protect against challenge with M. tuberculosis [9, 10] , to induce CD8 ϩ T cells cytotoxic for syngeneic macrophages infected with live M. tuberculosis, and to augment production of IFN-g and IL-12 in infected macrophages and responding T lymphocytes [11] .
We have conducted phase I studies with M. vaccae to assess its safety and immunogenicity as a possible vaccine to prevent mycobacterial infections in HIV-infected adults and children. A series of 3 doses given over 4-10 months was safe and well tolerated and elicited an in vitro immune response against mycobacterial antigens in some healthy and HIV-infected patients in the United States [12, 13] . Administration of 2 booster doses in a small group of these patients increased lymphocyte proliferative responses to mycobacterial antigens, compared with responses in nonimmunized control patients [14] .
In the present pilot study, we sought to determine whether 
Methods
Patients. Adult vaccine recipients and control patients were recruited from 4 sources in Lusaka, Zambia: staff of the University Teaching Hospital (UTH), staff and patients from the UTH HIV and sexually transmitted disease clinic, patients from Project San Francisco (an HIV counseling, testing, treatment, and research center), and patients from Hope House (an HIV counseling, testing, and residential facility). To be included in the study, patients were required to be HIV-infected by ELISA and have a CD4 lymphocyte count у200 cells/mm 3 at baseline. BCG-positive patients were defined by presence of a visible scar (written immunization records were not routinely available). BCG-negative patients were defined by absence of a visible scar and lack of a history of immunization. Other criteria included no current pregnancy or pregnancy planned for 6 months, no immunizations within 2 weeks, no current isoniazid prophylaxis, sputum smear-negativity for acid-fast bacteria, and body weight у55 kg.
Vaccine protocol. The study was conducted in 2 stages, as shown in figure 1. Stage A was an uncontrolled phase I safety study of 22 HIV-infected patients (11 BCG-positive and 11 BCG-negative). Baseline studies included determinations of CD4 lymphocyte count and HIV viral load, as well as skin tests with Mycobacterium avium sensitin (MAS) and PPD; for this phase of the study, BCGnegative patients were required to have an initial PPD reaction !5 mm in diameter.
Study patients received 3 doses of inactivated M. vaccae vaccine (lot MV001; Stanford Rook, London), at 0 month (dose 1), 2 months (dose 2), and 4 months (dose 3), from August through December 1996. The vaccine was administered as a 0. Vaccine recipients and control patients had phlebotomy for HIV viral load, CD4 lymphocyte count, and lymphocyte proliferation studies performed on the same day before dose 4 (pre-dose 4). Phlebotomy and PPD and MAS skin tests were repeated for vaccine recipients and control patients on the same day, 2 months after dose 5 (post-dose 5). PPD-negative control patients had a second PPD skin test performed 1 month later.
Skin tests. Skin tests were performed with 0.1 mL of MAS (MAS 10/2, filling lot 63; Statens Seruminstitut, Copenhagen) and 0.1 mL of M. tuberculosis PPD (Connaught Laboratories, Willowdale, Ontario, Canada) and were read 48-72 h later as millimeters of induration in the transverse diameter. A positive PPD skin test was defined as a reaction у5 mm in diameter. A PPD skin test conversion was defined as a change of у10 mm, from !5 mm to у5 mm in diameter.
Sputum smear for mycobacteria. Sputum samples were collected from the 22 vaccine recipients and 22 control patients and were stained using the Ziehl-Neelsen method.
Specimen processing. Whole blood was collected in 10-mL acid citrate dextrose vacutainer tubes (Becton-Dickinson, Franklin Lanes, NJ) and processed within 1-4 h from the time of collection. Peripheral blood mononuclear cells (PBMC) were separated from whole blood by density centrifugation over ficoll-hypaque (Pharmacia Biotech, Upsala, Sweden). After washing, PBMC were re- suspended in RPMI-1640 (BioWhittaker, Walkersville, MD) supplemented with 10% human AB serum (Sigma H2520; Sigma Chemical, St. Louis), 2 mM of glutamine, 25 mM of HEPES buffer, 50-mg/mL gentamicin sulfate, and 5-mg/mL polymyxin B (complete RPMI), and then were diluted in the same media to the appropriate cell concentration.
Lymphocyte proliferation assays. PBMC for lymphocyte proliferation assays were cultured at cells/well in 96-well cell 5 1 ϫ 10 culture plates. Final antigen concentrations in complete RPMI were as follows: M. vaccae sonicate (Stanford Rook), 5 mg/mL; MAS (MAS 10/2, lot 35; Statens Seruminstitut), 5 mg/mL; and M. tuberculosis short-term culture filtrate (STCF; batch 96-25, provided by Dr. Peter Andersen, Statens Seruminstitut), 2 mg/mL. Control wells contained complete RPMI cell suspensions alone and with phytohemagglutinin (PHA, Sigma H2520; Sigma) at 4 mg/mL. Cultures were performed in triplicate.
Microtiter plates were incubated for 96 h and then were pulsed with 1 mCi/well 3 H-labeled thymidine. After an additional 18-20 h incubation, all plates were frozen at Ϫ70ЊC until transported to the United States on dry ice. There the pulsed plates were thawed and harvested, and then 3 H-thymidine incorporation was measured by liquid scintigraphy. Results were expressed as either counts per minute (cpm) or a stimulation index derived by dividing the mean antigen-stimulated cpm by the mean nonantigen control cpm. Stimulation indices у3.0 were considered positive [15] .
Cell culture for IFN-g assays. PBMC for cytokine production were cultured at cells/well and were incubated for 5 days. HIV viral load. Plasma was collected and stored at Ϫ70ЊC. When the protocol required skin testing, plasma was drawn before skin tests were performed. Samples were shipped on dry ice to the United States, where HIV-1 viral load was determined with use of a branched-chain DNA (bDNA) assay with a detection limit of 500 HIV copies/mL (Chiron Diagnostics, Emeryville, CA). The technician was blinded to patient group.
Statistical analysis. Patient characteristics, HIV viral load, and lymphocyte proliferative responses to mycobacterial antigens were compared between vaccine and control groups with use of Fisher's exact test for categorical variables and Wilcoxon's rank sum or Student's t tests for continuous variables. Mean bDNA viral load changes were compared from baseline to follow-up within groups with use of the paired t test. Changes in vaccine induration between dose 1 and dose 5 within groups were compared with use of the Wilcoxon signed rank test. All statistical tests were two-sided, and was used to indicate statistical significance. Data were an-P р .05 alyzed with Stata statistical software (StataCorp, release 5.0, 1997; Stata, College Station, TX).
Results
Patients. Baseline characteristics of vaccine recipients and control patients for stage B are summarized in table 1. There were no significant differences between CD4 lymphocyte counts ( , Wilcoxon rank sum test) and HIV viral loads ( ) P = .3 P = .9 in vaccine recipients and control patients. Because BCG-negative control patients were not required to have a negative baseline PPD in stage B (BCG-negative vaccine recipients were required to have a negative baseline PPD in stage A), PPD reactions у5 mm in diameter were more common in control patients than in vaccine recipients ( ). No patients re-P = .05 ceived antiretroviral therapy or prophylaxis for opportunistic infections at any point in the study. Sputum smears for acidfast bacilli were negative for the 22 vaccine recipients and 22 control patients.
Vaccine side effects. Among vaccine recipients, induration at the vaccine site (table 2) at day 2 decreased with subsequent doses, with a significant difference between dose 1 and dose 5 ( , Wilcoxon's signed rank test). Median day 2 indu-P = .004 ration was greater for BCG-positive than for BCG-negative patients for doses 1-4 but was statistically significant only for dose 2 ( ). Among control patients, median induration P = .05 at the control injection site at day 2 and day 14 was 0 mm for both injections.
Among vaccine recipients, sore arm was reported after 4 (4%) of 110 vaccine doses, and skin breakdown or drainage was reported after 3 (3%) of 110 doses. Transient systemic side effects included malaise after 1 (0.9%) of 110 doses and headache after 3 (3%) of 110 doses. No vaccine recipient reported fever, and no fever was documented during study clinic visits. Among control patients, headache was reported after 4 (9%) of 44 doses and fever after 2 (5%) of 44 doses.
Among vaccine recipients, PPD conversions from the first PPD skin test (pre-dose 1) to the second PPD test (post-dose 3) occurred in 3 (14%) of 22 patients (1 BCG-positive and 2 BCG-negative); these were assumed to represent booster reactions in patients with prior mycobacterial infection, since we have shown previously that a 3-dose series of M. vaccae vaccinations does not result in PPD skin test conversions [12] . There were no additional PPD conversions following the third (post-dose 5) PPD skin test. Among control patients, skin tests were performed after dose 5; 22 patients had a first PPD skin test, 11 with PPD reactions of 0-4 mm in diameter had a second PPD test, and 1 (9%) of 11 had a PPD conversion that was assumed to represent a booster reaction. Overall, first or second PPD tests were positive for 7 (32%) of 22 vaccine recipients (5 BCG-positive and 2 BCG-negative) and 13 (59%) of 22 control patients (6 BCG-positive and 7 BCG-negative;
). P = .13 Plasma HIV assay. In stage A of the study, HIV viral load decreased significantly from baseline to post-dose 3 in the BCG-positive subgroup ( ), as shown in table 3 and P ! .001 figure 2 . In stage B of the study, HIV viral load increased steadily, with no significant difference between values for vaccine recipients and control patients.
Lymphocyte proliferation responses. Lymphocyte proliferation responses to M. vaccae sonicate are summarized in table 4. Median absolute responses after dose 5 were higher in M. vaccae vaccine recipients than in control patients ( ). In P = .001 the subgroup analysis, differences were significant for BCGpositive M. vaccae vaccine recipients compared with BCG-positive control patients ( ) but not for BCG-negative M. P = .002 vaccae vaccine recipients compared with BCG-negative control patients ( ). Stimulation indices after dose 5 were also P = .2 significantly higher for M. vaccae vaccine recipients than for control patients ( ). In the subgroup analysis, differences P ! .001 were significant for both BCG-positive ( ) and BCG-P = .001 negative patients ( ). Positive stimulation indices after P = .05 dose 5 were noted in 19 (86%) of the 22 M. vaccae vaccine recipients and 7 (32%) of the 22 control patients ( ). P = .001 Median absolute proliferation responses to M. vaccae sonicate pre-dose 4 were higher in all patients with positive first or second PPD reactions than in all patients with negative first and second PPD reactions ( ); post-dose 5 responses P = .001 Table 3 . Mean HIV viral load (log 10 ) in Mycobacterium vaccae vaccine recipients and control patients. were not different among all PPD-positive and all PPD-negative patients (
). Among PPD-negative patients, absolute pro-P = .1 liferation responses to M. vaccae sonicate after dose 5 were higher in M. vaccae vaccine recipients than in control patients ( ) . P = .01
Lymphocyte proliferation responses to MAS and STCF (secreted mycobacterial proteins similar to PPD) were higher pre-dose 4 among control patients than among vaccine recipients ( for STCF; for MAS), consistent with the P = .06 P = .08 higher rate of positive PPD skin test reactions among control patients. There were no significant differences after dose 5. Responses to STCF and MAS correlated with first or second PPD skin test reactions у5 mm (
). There was no significant P р .04 difference between vaccine recipients and control patients in proliferative responses to PHA, and there was a decline in the magnitude of the responses from dose 4 to dose 5.
IFN-g responses. Median absolute values for M. vaccae sonicate-induced IFN-g production post-dose 5 were not significantly different for vaccine recipients and control patients (data not shown). Positive M. vaccae sonicate indices post-dose 5 were noted in 5 (23%) of 22 vaccine recipients and 1 (5%) of 22 control patients ( ). Median absolute values for STCF-P = .19 and MAS-induced IFN-g production were higher in control patients than in vaccine recipients and correlated with positive first or second PPD skin tests.
Discussion
This study demonstrates that a series of 5 doses of inactivated M. vaccae is safe and well tolerated among both BCG-negative and BCG-positive HIV-infected patients in a developing country with a high background rate of tuberculosis. Cellular immune responses to the mycobacterial vaccine antigen, M. vaccae sonicate, were greater in vaccine recipients than in control patients. Responses were greater in BCG-positive M. vaccae recipients than in BCG-negative M. vaccae recipients and were also greater in PPD-positive than in PPD-negative M. vaccae recipients, indicating the role of prior immunologic priming.
Among control patients, rates of positive PPD reactions and lymphocyte proliferation responses to STCF and MAS were higher than among M. vaccae recipients, which implies that they either were more mycobacteria-experienced or had enhanced cellular immune function against mycobacteria (related, e.g., to genetic factors or stage of HIV infection). This potential bias strengthens the significance of the observed increase in lymphocyte proliferation responses to M. vaccae sonicate among vaccine recipients. Overall cellular immune competence, measured by mitogenic responses to PHA, did not differ between vaccine and control patient groups.
As for many effective vaccines in current use, there is no established in vitro surrogate to test the immunogenicity of BCG or newer candidate mycobacterial vaccines. However, CD4 lymphocyte function is critical to host control of infection with M. tuberculosis, and both in vitro proliferative and IFNg responses by lymphocytes to vaccine antigens are considered important measures of mycobacterial vaccine immunogenicity [16] . Thus, the increase in lymphocyte proliferation response to M. vaccae sonicate observed in M. vaccae recipients suggests that M. vaccae induces a biologically relevant immune response in HIV-infected patients.
Lymphocyte proliferation may be impaired in HIV infection [17] , so it is not surprising that the absolute responses observed in HIV-infected vaccine recipients were lower than those reported for healthy BCG vaccine recipients [16, 18] and that IFN-g responses were not observed in all patients. Because we do not have controlled immunogenicity data from the first 3 doses of the vaccine, we are unable to say how many doses of vaccine are necessary to elicit the observed responses. It will also be important to determine whether the observed responses are specific to mycobacteria: this might be determined either by using an antigenic control group (e.g., tetanus) or by retesting cellular immune responses after a longer interval to detect a memory response.
The transient decrease in HIV viral load detected in BCGpositive patients after dose 3 remains unexplained. Possible explanations include a transient upregulation of HIV viral load at baseline, due to recent PPD testing in patients with latent mycobacterial infection [19] , a transient downregulation of HIV replication after dose 3 in patients coinfected with HIV and M. tuberculosis, or a random event. Because HIV viral loads were determined 2 months after immunization, we may have failed to detect other transient effects of M. vaccae immunization on viral load.
Our studies directed toward use of a multiple-dose schedule of inactivated M. vaccae to prevent tuberculosis [12, 13] are distinct from other investigational studies that used this vaccine, including a trial of (single-dose) M. vaccae as an adjunct to standard drug therapy for pulmonary tuberculosis [20] . First, the rationale for our use of this heat-inactivated whole-cell vaccine was to induce a cross-protective mycobacterial immune response similar to that following natural infection with nontuberculous mycobacteria (NTM), rather than to alter polarized cellular immune responses from a Th2 to a Th1 pattern during active tuberculous disease [21] [22] [23] . Second, our protocol employed a multiple-dose series of M. vaccae rather than a single dose, because inactivated whole-cell bacterial vaccines must generally be administered in a multiple-dose schedule to induce a significant immune response [24, 25] . Both epidemiological and experimental animal data indicate that infection with heterologous strains of NTM provides measurable cross-protection against tuberculosis [26] . Thus, if mycobacterial immunization with M. vaccae can simulate natural infection with NTM, protection against tuberculosis might be predicted. Because natural infection with NTM also provides some protection against subsequent NTM infection, immunization with M. vaccae might be similarly effective in preventing diseases due to M. avium. Whether the magnitude or specificity of the cellular immune response we observed after M. vaccae immunization is equal to that with naturally acquired infection with NTM is not known.
Both live and inactivated vaccines might be capable of simulating natural infection with NTM. Multiple-dose schedules of inactivated mycobacterial vaccines have been shown to provide protection against M. tuberculosis in both animals and humans, although these vaccines are not currently being investigated for general use in replacing BCG [27, 28] . Over 100,000 children were immunized with multiple doses of inactivated mycobacterial vaccines in Italy in the 1950s. Although documentation was inadequate, a follow-up study of 18,000 immunized children showed substantial protection against tuberculosis, an effect judged to be equal to that of BCG [27] . A multiple-dose schedule of an inactivated-NTM vaccine has also been shown to be effective in the therapy for leprosy and is currently being investigated in large studies for the prevention of leprosy [29] .
Data on inactivated M. vaccae are available from animal studies and support the hypothesis that immunization can induce a protective immune response against M. tuberculosis. Immunization of mice with heat-killed M. vaccae elicits a dosedependent protective response in mice subsequently challenged with M. tuberculosis [10] . In this study, a low-dose inoculum (10 7 organisms) was associated with induction of a predominantly Th1 cytokine profile and protection, whereas a highdose inoculum (10 9 organisms) induced a mixed Th1 and/or Th2 response and more rapid demise.
M. vaccae immunization in mice also stimulates CD8 ϩ cytotoxic T cell responses to M. tuberculosis-infected macrophages [11] . Effector activity against infected macrophages was lost 3-4 weeks after immunization, but when CD8 ϩ T cells were restimulated with heat-killed M. tuberculosis prior to assay of cytotoxicity, cytotoxic T-lymphocyte activity reappeared, suggesting that the effector cells had arisen from M. vaccae-primed memory cells [11] .
The ultimate solution to an improved vaccine for the prevention of tuberculosis in healthy populations may rest with secreted protein vaccines, live attenuated vaccines, or DNA vaccines [30] [31] [32] . However, there are no specific data to indicate that these vaccines are more likely than an inactivated NTM vaccine to provide protection superior to that of BCG. Furthermore, several of these approaches are presently limited by 2 problems relevant to mycobacterial immunization in HIVinfected populations.
First, immune responses to relatively homogeneous mycobacterial vaccines may be genetically restricted and therefore may be further curtailed in HIV-infected persons with limited T cell repertoires. Second, live attenuated vaccines have the potential to cause vaccine-strain infection in HIV-infected persons; accurate assessment of this risk will require extensive studies. The investigational M. vaccae vaccine used in this study avoids these problems. HIV-infected patients are capable of responding to this heterogeneous heat-killed vaccine, which does not carry a risk of vaccine-strain infection. Further studies with a multiple-dose series of M. vaccae vaccinations for the prevention of HIV-associated tuberculosis are warranted.
